Gupta P, Zhao H, Hoang B and Schwartz EL. Targeting the untargetable: RB1-deficient tumors are vulnerable to Skp2 ubiquitin ligase inhibition. British J Cancer, 2022; in press.
Wang J, Aldahamsheh O, Ferrena A, Borjihan H, Singla A, Yaguare S, Singh S, Viscarret V, Tingling J, Zi X, Lo Y, Gorlick R, Zheng D, Schwartz EL, Zhao H, Yang DS, Geller DS and Hoang BH. The interaction of Skp2 with p27 enhances the progression and stemness of osteosarcoma. Annals NY Acad Sci, 2021; 1490:90-104.
Zhao H, Iqbal N, Sukrithan V, Nicholas C, Xue Y, Yu C, Locker J, Zou J, Schwartz EL and Zhu L. Targeted inhibition of the E3 ligase SCFSkp2/Cks1 has antitumor activity in RB1-deficient human and mouse small cell lung cancer (SCLC). Cancer Research, 2020; 80:2355-67.
Wang J, Sato K, O’Donnell E, Singla A, Yaguare S, Aldahamsheh O, Batko B, Borjihan H, Tingling J, Zhang J, Weiser DA, Loeb DM, Gorlick R, Schwartz EL, Yang R, Zi X, Zhao H, Geller DS and Hoang BH. Skp2 depletion reduces tumor-initiating properties and promotes apoptosis in synovial sarcoma. Translational Oncology, 2020; 13:100809.
Sironi J, Aranda A, Nordstrøm L, and Schwartz EL. Lysosome membrane permeabilization and disruption of mTOR-lysosome interaction are associated with the inhibition of lung cancer cell proliferation by a chloroquinoline analog. Molecular Pharmacology, 2019; 95:127-138.